FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Cohen Neil Harris 2. Issuer Name and Ticker or Trading Symbol Chemomab Therapeutics Ltd. [ CMMB ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)
C/O CHEMOMAB THERAPEUTICS LTD.,, 1 KENDALL SQ, BLDG 1400E, STE 14-105
3. Date of Earliest Transaction (MM/DD/YYYY)
11/16/2022
(Street)
CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares (1) 11/16/2022    S    2409 (2) D $2  10000 (3) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase American Depositary Shares (4) $3.53  3/7/2022    A     6820       (5) 3/7/2032  American Depositary Shares (1) 6820  $0  6820  D   
Option to Purchase American Depositary Shares (4) $27.26  4/19/2021    A     11884       (6) 4/19/2031  American Depositary Shares (1) 11884  $0  11884  D   
Option to Purchase American Depositary Shares (4) $13.17  3/16/2021    A     688       (7) 7/15/2030  American Depositary Shares (1) 688  $0  688  D   

Explanation of Responses:
(1)  Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
(2)  The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
(3)  Based upon the 12,409 ADSs previously held as reported by Mr. Neil Cohen on Form 4 filed with the SEC on May 19, 2022.
(4)  No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
(5)  These options vest and become exercisable in their entirety on March 16, 2023 subject to the Reporting Person's continued service.
(6)  These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
(7)  These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Cohen Neil Harris
C/O CHEMOMAB THERAPEUTICS LTD.,
1 KENDALL SQ, BLDG 1400E, STE 14-105
CAMBRIDGE, MA 02139
X



Signatures
/s/ Neil Cohen 11/18/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Chemomab Therapeutics Charts.
Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Chemomab Therapeutics Charts.